Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines

Abstract

abbreviatioNs BCA = bicinchoninic acid; CSC = Cell Systems Corporation; DHA = docosahexaenoic acid; DMEM = Dulbecco's modified essential medium; DPA = docosapentaenoic acid; ED 50 = median effective dose; EMEM = Eagle's minimum essential medium; EPA = eicosapentaenoic acid; FBS = fetal bovine serum; HBMEC = human brain microvascular endothelial cell; HCCMEC = human cerebral cortex microvascular endothelial cell; OD = optical density; PARP = poly (ADP-ribose) polymerase; PBS = phosphate-buffered saline; PUFA = polyunsaturated fatty acid. obJect Glioblastoma is a rapidly infiltrating tumor that consistently rematerializes despite various forms of aggressive treatment. Brain tumors are commonly treated with alkylating drugs, such as lomustine, which are chemotherapeutic agents. Use of these drugs, however, is associated with serious side effects. To reduce the side effects, one approach is to combine lower doses of chemotherapeutic drugs with other nontoxic anticancer agents. In this study, using glioblastoma cell lines, the authors investigated the anticancer effects of lomustine, alone and in combination with docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid normally abundant in the brain and known for its anticancer potential. methods Cells were cultured from 3 human-derived tumor cell lines (U87-MG, DB029, and MHBT161) and supplemented with either DHA or lomustine to determine the growth inhibitory potential using WST-1, a mitochondrial functional indicator. Human-derived cerebral cortex microvascular endothelial cells served as a normal phenotypic control. Cellular incorporation of DHA was analyzed by gas chromatography. Using flow cytometric analysis, the DHA and/or lomustine effect on induction of apoptosis and/or necrosis was quantified; subsequently, the DHA and lomustine effect on cell cycle progression was also assessed. Western blot analysis confirmed the role of downstream cellular targets. results U87-MG growth was inhibited with the supplementation of either DHA (ED 50 68.3 mM) or lomustine (ED 50 68.1 mM); however, growth inhibition was enhanced when U87-MG cells were administered equimolar doses of each compound, resulting in nearly total growth inhibition at 50 mM. Gas chromatography analysis of the fatty acid profile in DHA-supplemented U87-MG cells resulted in a linear dose-dependent increase in DHA incorporation (< 60 mM). The combination of DHA and lomustine potently induced U87-MG apoptosis and necrosis as indicated by flow cytometric analysis. Activation of caspase-3 and poly (ADP-ribose) polymerase (PARP) was evident in lomustine-treated U87-MG cells, although this activation did not appear to be dependent on DHA supplementation. Additionally, lomustine-treated cells' growth arrested in the G 2 /M cell cycle stage, regardless of the presence of DHA. Similar to the U87-MG observations, the combination of DHA and lomustine resulted in growth inhibition of 2 additional human-derived glioblastoma cell lines, DB029 and MHBT161. Importantly, in primary human-derived cerebral corte...

Glioblastoma Multiforme: an Advanced Analysis of 153 Patients and Review of the Literature

“…In a recent experimental study, Harvey et al assessed the anticancer properties of CCNU in glioblastoma cell lines, and found that the combination of docosahexaenoic acid (DHA) and CCNU strongly induced Uppsala 87 malignant glioma (U87-MG0 apoptosis and necrosis as indicated by flow cytometric analysis. 35 They suggested a potential role for a…”

Cancer Chemoprevention by Phytochemicals: Nature’s Healing Touch

“…These lipids, such as the fatty acid docosahexaenoic acid, have been observed to demonstrate potent anticancer properties against a variety of cancer types such as breast cancer, ovarian cancer, glioblastomas, etc. [ 211 , 212 , 213 , 214 ]. The nanocapsules, comprising shells of bioactive lipids, are able to deliver drugs and other biologically sensitive molecules to specific cells or organs, thus enhancing the potency and cancer therapeutic potential [ 211 , 215 ].…”

Docosahexaenoic acid–mediated, targeted and sustained brain delivery of curcumin microemulsion

“…Such synergistic behavior of DHA with arsenic acid in number of cell lines (Baumgartner et al, 2004) and with paclitaxel in BT-474 and SK-BR-3 breast cell lines that have been linked to lipid peroxidation (Menendez et al, 2005) is reported. DHA-mediated enhanced uptake of CUR by modulating plasma membranes in glioblastomas could have also played a critical role (Harvey et al, 2015). Studies have shown that DHA incorporation changed the chemical and physical properties of cell membrane phospholipids to enhance uptake of various anticancer drugs, including vincristine in a drug-resistant neuroblastoma cell line (Ikushima et al, 1990).…”